http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Tue, 12 May 2026 07:30:57 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/Corporate+News/SAB+Biotherapeutics+reports+Q1+2026+results%2C+enrollment+progress/26473051.html <p>SAB Biotherapeutics, Inc. (NASDAQ: SABS) reported first quarter 2026 financial results and provided updates on its SAFEGUARD clinical trial for type 1 diabetes treatment SAB-142.</p><p>The company reported a net loss of $18.9 million for the quarter ended March 31, 2026, compared to a $5.2 million loss in the same period last year. Research and development expenses increased to $13.4 million from $7.7 million year-over-year, driven by investments in the SAB-142 program.</p><p>SAB Biotherapeutics maintains a cash position of $217.6 million as of March 31, 2026, following a $95 million public offering completed in March. The company stated this provides operational runway http://www.streetinsider.com/Corporate+News/SAB+Biotherapeutics+reports+Q1+2026+results%2C+enrollment+progress/26473051.html Tue, 12 May 2026 07:30:57 -0400 SABS SABSW http://www.streetinsider.com/Corporate+News/SAB+Biotherapeutics+reports+Q1+2026+results%2C+enrollment+progress/26473051.html <p>SAB Biotherapeutics, Inc. (NASDAQ: SABS) reported first quarter 2026 financial results and provided updates on its SAFEGUARD clinical trial for type 1 diabetes treatment SAB-142.</p><p>The company reported a net loss of $18.9 million for the quarter ended March 31, 2026, compared to a $5.2 million loss in the same period last year. Research and development expenses increased to $13.4 million from $7.7 million year-over-year, driven by investments in the SAB-142 program.</p><p>SAB Biotherapeutics maintains a cash position of $217.6 million as of March 31, 2026, following a $95 million public offering completed in March. The company stated this provides operational runway http://www.streetinsider.com/Corporate+News/SAB+Biotherapeutics+reports+Q1+2026+results%2C+enrollment+progress/26473051.html Tue, 12 May 2026 07:30:57 -0400 SABS SABSW http://www.streetinsider.com/Press+Releases/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html <p align="center"><em>Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027</em></p> <p align="center"><em>Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes</em></p> <p align="center"><em>Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities</em></p> <p align="center"><em>Conference call today at 8:30 AM ET</em></p> <p>MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a http://www.streetinsider.com/Press+Releases/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html Tue, 12 May 2026 07:30:00 -0400 A.09642568 A.20822773 O.20370956 O.20371933 O.49911890 SABS SABSW http://www.streetinsider.com/Press+Releases/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html <p align="center"><em>Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027</em></p> <p align="center"><em>Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes</em></p> <p align="center"><em>Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities</em></p> <p align="center"><em>Conference call today at 8:30 AM ET</em></p> <p>MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a http://www.streetinsider.com/Press+Releases/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html Tue, 12 May 2026 07:30:00 -0400 A.09642568 A.20822773 O.20370956 O.20371933 O.49911890 SABS SABSW http://www.streetinsider.com/Press+Releases/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html <p align="center"><em>Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027</em></p> <p align="center"><em>Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes</em></p> <p align="center"><em>Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities</em></p> <p align="center"><em>Conference call today at 8:30 AM ET</em></p> <p>MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a http://www.streetinsider.com/Press+Releases/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html Tue, 12 May 2026 07:30:00 -0400 A.09642568 A.20822773 O.20370956 O.20371933 O.49911890 SABS SABSW http://www.streetinsider.com/Press+Releases/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html <p align="center"><em>Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027</em></p> <p align="center"><em>Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes</em></p> <p align="center"><em>Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities</em></p> <p align="center"><em>Conference call today at 8:30 AM ET</em></p> <p>MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a http://www.streetinsider.com/Press+Releases/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html Tue, 12 May 2026 07:30:00 -0400 A.09642568 A.20822773 O.20370956 O.20371933 O.49911890 SABS SABSW http://www.streetinsider.com/Press+Releases/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html <p align="center"><em>Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027</em></p> <p align="center"><em>Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes</em></p> <p align="center"><em>Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities</em></p> <p align="center"><em>Conference call today at 8:30 AM ET</em></p> <p>MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a http://www.streetinsider.com/Press+Releases/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html Tue, 12 May 2026 07:30:00 -0400 A.09642568 A.20822773 O.20370956 O.20371933 O.49911890 SABS SABSW http://www.streetinsider.com/Press+Releases/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html <p align="center"><em>Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027</em></p> <p align="center"><em>Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes</em></p> <p align="center"><em>Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities</em></p> <p align="center"><em>Conference call today at 8:30 AM ET</em></p> <p>MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a http://www.streetinsider.com/Press+Releases/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html Tue, 12 May 2026 07:30:00 -0400 A.09642568 A.20822773 O.20370956 O.20371933 O.49911890 SABS SABSW http://www.streetinsider.com/Press+Releases/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html <p align="center"><em>Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027</em></p> <p align="center"><em>Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes</em></p> <p align="center"><em>Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities</em></p> <p align="center"><em>Conference call today at 8:30 AM ET</em></p> <p>MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a http://www.streetinsider.com/Press+Releases/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html Tue, 12 May 2026 07:30:00 -0400 A.09642568 A.20822773 O.20370956 O.20371933 O.49911890 SABS SABSW http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html <p align="center"><em>Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027</em></p> <p align="center"><em>Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes</em></p> <p align="center"><em>Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities</em></p> <p align="center"><em>Conference call today at 8:30 AM ET</em></p> <p>MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html Tue, 12 May 2026 07:30:00 -0400 A.09642568 A.20822773 O.20370956 O.20371933 O.49911890 SABS SABSW http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html <p align="center"><em>Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027</em></p> <p align="center"><em>Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes</em></p> <p align="center"><em>Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities</em></p> <p align="center"><em>Conference call today at 8:30 AM ET</em></p> <p>MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html Tue, 12 May 2026 07:30:00 -0400 A.09642568 A.20822773 O.20370956 O.20371933 O.49911890 SABS SABSW http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html <p align="center"><em>Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027</em></p> <p align="center"><em>Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes</em></p> <p align="center"><em>Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities</em></p> <p align="center"><em>Conference call today at 8:30 AM ET</em></p> <p>MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html Tue, 12 May 2026 07:30:00 -0400 A.09642568 A.20822773 O.20370956 O.20371933 O.49911890 SABS SABSW http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html <p align="center"><em>Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027</em></p> <p align="center"><em>Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes</em></p> <p align="center"><em>Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities</em></p> <p align="center"><em>Conference call today at 8:30 AM ET</em></p> <p>MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html Tue, 12 May 2026 07:30:00 -0400 A.09642568 A.20822773 O.20370956 O.20371933 O.49911890 SABS SABSW http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html <p align="center"><em>Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027</em></p> <p align="center"><em>Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes</em></p> <p align="center"><em>Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities</em></p> <p align="center"><em>Conference call today at 8:30 AM ET</em></p> <p>MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html Tue, 12 May 2026 07:30:00 -0400 A.09642568 A.20822773 O.20370956 O.20371933 O.49911890 SABS SABSW http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html <p align="center"><em>Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027</em></p> <p align="center"><em>Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes</em></p> <p align="center"><em>Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities</em></p> <p align="center"><em>Conference call today at 8:30 AM ET</em></p> <p>MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html Tue, 12 May 2026 07:30:00 -0400 A.09642568 A.20822773 O.20370956 O.20371933 O.49911890 SABS SABSW http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html <p align="center"><em>Continued site activation in registrational SAFEGUARD trial of SAB-142; enrollment ongoing and on track to be completed by end of 2026 with topline data expected in 2H 2027</em></p> <p align="center"><em>Reported additional Phase 1 data for SAB-142 demonstrating C-peptide preservation and improvement in glycemic control in established autoimmune type 1 diabetes</em></p> <p align="center"><em>Strong cash position, reflecting $95 million public offering proceeds, with operational runway through 2028 to support execution of SAFEGUARD and pre-commercial activities</em></p> <p align="center"><em>Conference call today at 8:30 AM ET</em></p> <p>MIAMI, May 12, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a http://www.streetinsider.com/Globe+Newswire/SAB+BIO+Reports+Q1+2026+Financial+Results+and+Recent+Business+Highlights/26473039.html Tue, 12 May 2026 07:30:00 -0400 A.09642568 A.20822773 O.20370956 O.20371933 O.49911890 SABS SABSW http://www.streetinsider.com/Press+Releases/SAB+BIO+to+Host+First+Quarter+2026+Financial+Results+Conference+Call+and+Webcast+on+May+12%2C+2026%2C+08%3A30+AM+ET/26430540.html <p>MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6LSQC8CZMWg5rhoPKfGTffWcgGm_uZZLvSADA5C7XFhbRoNnaHDzw0FWScmou_2nVhcQFemDL_g63I94eD_ExKpewlhgaOK7TcWpD7SLQgM6Fn7yOboSt482PegikcbkyRhnZcOUjzsFIayQzQSjCQdP4BFF9Qp-NT8NbeYXKzK994rYrLgAC4GDqb7yCE51loiEqRGBynPRvDHlLuu-I67FJ-Zl01YauM60UeS2H4N62I4X1kMBMbDbPtXAZoqtqptf91s1FNFiDN_lQBvh9g==" rel="nofollow" target="_blank">SABS</a>), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its first quarter 2026 financial results will be issued in the morning of Tuesday, May 12, 2026. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates.</p> <p>To access the live conference call, participants may register <a target="_blank" href="https://www.globenewswire.com/Tracker?data=t7hTCxAQoDhIaWWvfGZcQ-G1muD2ZEditBQwgRxLkrM8SVW0IKvh_Xkl9jx4i73IYkDhH1RiaUX8NtZbuDl0rWMxf3vzPLramxbujuNvzExIkPWc84HVB9bOkLAhWExXxSKCAk60sYUtBYb8efUtRA==" rel="nofollow" target="_blank">here</a>.</p> <p align="justify"><strong>Conference Details:</strong></p> <p http://www.streetinsider.com/Press+Releases/SAB+BIO+to+Host+First+Quarter+2026+Financial+Results+Conference+Call+and+Webcast+on+May+12%2C+2026%2C+08%3A30+AM+ET/26430540.html Tue, 05 May 2026 08:30:00 -0400 O.49911890 SABS SABSW http://www.streetinsider.com/Press+Releases/SAB+BIO+to+Host+First+Quarter+2026+Financial+Results+Conference+Call+and+Webcast+on+May+12%2C+2026%2C+08%3A30+AM+ET/26430540.html <p>MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6LSQC8CZMWg5rhoPKfGTffWcgGm_uZZLvSADA5C7XFhbRoNnaHDzw0FWScmou_2nVhcQFemDL_g63I94eD_ExKpewlhgaOK7TcWpD7SLQgM6Fn7yOboSt482PegikcbkyRhnZcOUjzsFIayQzQSjCQdP4BFF9Qp-NT8NbeYXKzK994rYrLgAC4GDqb7yCE51loiEqRGBynPRvDHlLuu-I67FJ-Zl01YauM60UeS2H4N62I4X1kMBMbDbPtXAZoqtqptf91s1FNFiDN_lQBvh9g==" rel="nofollow" target="_blank">SABS</a>), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its first quarter 2026 financial results will be issued in the morning of Tuesday, May 12, 2026. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates.</p> <p>To access the live conference call, participants may register <a target="_blank" href="https://www.globenewswire.com/Tracker?data=t7hTCxAQoDhIaWWvfGZcQ-G1muD2ZEditBQwgRxLkrM8SVW0IKvh_Xkl9jx4i73IYkDhH1RiaUX8NtZbuDl0rWMxf3vzPLramxbujuNvzExIkPWc84HVB9bOkLAhWExXxSKCAk60sYUtBYb8efUtRA==" rel="nofollow" target="_blank">here</a>.</p> <p align="justify"><strong>Conference Details:</strong></p> <p http://www.streetinsider.com/Press+Releases/SAB+BIO+to+Host+First+Quarter+2026+Financial+Results+Conference+Call+and+Webcast+on+May+12%2C+2026%2C+08%3A30+AM+ET/26430540.html Tue, 05 May 2026 08:30:00 -0400 O.49911890 SABS SABSW http://www.streetinsider.com/Press+Releases/SAB+BIO+to+Host+First+Quarter+2026+Financial+Results+Conference+Call+and+Webcast+on+May+12%2C+2026%2C+08%3A30+AM+ET/26430540.html <p>MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6LSQC8CZMWg5rhoPKfGTffWcgGm_uZZLvSADA5C7XFhbRoNnaHDzw0FWScmou_2nVhcQFemDL_g63I94eD_ExKpewlhgaOK7TcWpD7SLQgM6Fn7yOboSt482PegikcbkyRhnZcOUjzsFIayQzQSjCQdP4BFF9Qp-NT8NbeYXKzK994rYrLgAC4GDqb7yCE51loiEqRGBynPRvDHlLuu-I67FJ-Zl01YauM60UeS2H4N62I4X1kMBMbDbPtXAZoqtqptf91s1FNFiDN_lQBvh9g==" rel="nofollow" target="_blank">SABS</a>), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its first quarter 2026 financial results will be issued in the morning of Tuesday, May 12, 2026. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates.</p> <p>To access the live conference call, participants may register <a target="_blank" href="https://www.globenewswire.com/Tracker?data=t7hTCxAQoDhIaWWvfGZcQ-G1muD2ZEditBQwgRxLkrM8SVW0IKvh_Xkl9jx4i73IYkDhH1RiaUX8NtZbuDl0rWMxf3vzPLramxbujuNvzExIkPWc84HVB9bOkLAhWExXxSKCAk60sYUtBYb8efUtRA==" rel="nofollow" target="_blank">here</a>.</p> <p align="justify"><strong>Conference Details:</strong></p> <p http://www.streetinsider.com/Press+Releases/SAB+BIO+to+Host+First+Quarter+2026+Financial+Results+Conference+Call+and+Webcast+on+May+12%2C+2026%2C+08%3A30+AM+ET/26430540.html Tue, 05 May 2026 08:30:00 -0400 O.49911890 SABS SABSW http://www.streetinsider.com/Globe+Newswire/SAB+BIO+to+Host+First+Quarter+2026+Financial+Results+Conference+Call+and+Webcast+on+May+12%2C+2026%2C+08%3A30+AM+ET/26430540.html <p>MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6LSQC8CZMWg5rhoPKfGTffWcgGm_uZZLvSADA5C7XFhbRoNnaHDzw0FWScmou_2nVhcQFemDL_g63I94eD_ExKpewlhgaOK7TcWpD7SLQgM6Fn7yOboSt482PegikcbkyRhnZcOUjzsFIayQzQSjCQdP4BFF9Qp-NT8NbeYXKzK994rYrLgAC4GDqb7yCE51loiEqRGBynPRvDHlLuu-I67FJ-Zl01YauM60UeS2H4N62I4X1kMBMbDbPtXAZoqtqptf91s1FNFiDN_lQBvh9g==" rel="nofollow" target="_blank">SABS</a>), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its first quarter 2026 financial results will be issued in the morning of Tuesday, May 12, 2026. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates.</p> <p>To access the live conference call, participants may register <a target="_blank" href="https://www.globenewswire.com/Tracker?data=t7hTCxAQoDhIaWWvfGZcQ-G1muD2ZEditBQwgRxLkrM8SVW0IKvh_Xkl9jx4i73IYkDhH1RiaUX8NtZbuDl0rWMxf3vzPLramxbujuNvzExIkPWc84HVB9bOkLAhWExXxSKCAk60sYUtBYb8efUtRA==" rel="nofollow" target="_blank">here</a>.</p> <p align="justify"><strong>Conference Details:</strong></p> <p http://www.streetinsider.com/Globe+Newswire/SAB+BIO+to+Host+First+Quarter+2026+Financial+Results+Conference+Call+and+Webcast+on+May+12%2C+2026%2C+08%3A30+AM+ET/26430540.html Tue, 05 May 2026 08:30:00 -0400 O.49911890 SABS SABSW http://www.streetinsider.com/Globe+Newswire/SAB+BIO+to+Host+First+Quarter+2026+Financial+Results+Conference+Call+and+Webcast+on+May+12%2C+2026%2C+08%3A30+AM+ET/26430540.html <p>MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6LSQC8CZMWg5rhoPKfGTffWcgGm_uZZLvSADA5C7XFhbRoNnaHDzw0FWScmou_2nVhcQFemDL_g63I94eD_ExKpewlhgaOK7TcWpD7SLQgM6Fn7yOboSt482PegikcbkyRhnZcOUjzsFIayQzQSjCQdP4BFF9Qp-NT8NbeYXKzK994rYrLgAC4GDqb7yCE51loiEqRGBynPRvDHlLuu-I67FJ-Zl01YauM60UeS2H4N62I4X1kMBMbDbPtXAZoqtqptf91s1FNFiDN_lQBvh9g==" rel="nofollow" target="_blank">SABS</a>), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its first quarter 2026 financial results will be issued in the morning of Tuesday, May 12, 2026. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates.</p> <p>To access the live conference call, participants may register <a target="_blank" href="https://www.globenewswire.com/Tracker?data=t7hTCxAQoDhIaWWvfGZcQ-G1muD2ZEditBQwgRxLkrM8SVW0IKvh_Xkl9jx4i73IYkDhH1RiaUX8NtZbuDl0rWMxf3vzPLramxbujuNvzExIkPWc84HVB9bOkLAhWExXxSKCAk60sYUtBYb8efUtRA==" rel="nofollow" target="_blank">here</a>.</p> <p align="justify"><strong>Conference Details:</strong></p> <p http://www.streetinsider.com/Globe+Newswire/SAB+BIO+to+Host+First+Quarter+2026+Financial+Results+Conference+Call+and+Webcast+on+May+12%2C+2026%2C+08%3A30+AM+ET/26430540.html Tue, 05 May 2026 08:30:00 -0400 O.49911890 SABS SABSW http://www.streetinsider.com/Globe+Newswire/SAB+BIO+to+Host+First+Quarter+2026+Financial+Results+Conference+Call+and+Webcast+on+May+12%2C+2026%2C+08%3A30+AM+ET/26430540.html <p>MIAMI, May 05, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=6LSQC8CZMWg5rhoPKfGTffWcgGm_uZZLvSADA5C7XFhbRoNnaHDzw0FWScmou_2nVhcQFemDL_g63I94eD_ExKpewlhgaOK7TcWpD7SLQgM6Fn7yOboSt482PegikcbkyRhnZcOUjzsFIayQzQSjCQdP4BFF9Qp-NT8NbeYXKzK994rYrLgAC4GDqb7yCE51loiEqRGBynPRvDHlLuu-I67FJ-Zl01YauM60UeS2H4N62I4X1kMBMbDbPtXAZoqtqptf91s1FNFiDN_lQBvh9g==" rel="nofollow" target="_blank">SABS</a>), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that its first quarter 2026 financial results will be issued in the morning of Tuesday, May 12, 2026. Management will host a conference call and webcast at 8:30 AM ET to discuss the results and provide business updates.</p> <p>To access the live conference call, participants may register <a target="_blank" href="https://www.globenewswire.com/Tracker?data=t7hTCxAQoDhIaWWvfGZcQ-G1muD2ZEditBQwgRxLkrM8SVW0IKvh_Xkl9jx4i73IYkDhH1RiaUX8NtZbuDl0rWMxf3vzPLramxbujuNvzExIkPWc84HVB9bOkLAhWExXxSKCAk60sYUtBYb8efUtRA==" rel="nofollow" target="_blank">here</a>.</p> <p align="justify"><strong>Conference Details:</strong></p> <p http://www.streetinsider.com/Globe+Newswire/SAB+BIO+to+Host+First+Quarter+2026+Financial+Results+Conference+Call+and+Webcast+on+May+12%2C+2026%2C+08%3A30+AM+ET/26430540.html Tue, 05 May 2026 08:30:00 -0400 O.49911890 SABS SABSW http://www.streetinsider.com/Press+Releases/SAB+BIO+to+Present+Additional+Data+Supporting+the+Unique+Profile+of+SAB-142+at+the+2026+Immunology+of+Diabetes+Society+Congress/26315278.html <p>MIAMI, April 15, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gbS_jsZOFMqa0pkvyM2-DxkiVRhNWSd48G20tCVO2qMdU5dmLnxdOSwLYfobbegAC0OERcXfimYYXYZbo9K2oSvyUExctEyAZHbcNVLs2NARddp5NvRLmlPI6va76INZuOjJhg8g_Rkx-J8lIQkga-AoOrBkItkMv0sw7_FWZBJlz525RUP_axAWl83G8Qp-Mt7H1F16Aje7kClIcvpwW3by4xNhBFlUYQKIPTbdyPbFpGBeoObdMR5mCPXB1iI_" rel="nofollow" target="_blank">SABS</a>), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company will give an oral presentation and multiple poster presentations at the 21st Immunology of Diabetes Society (IDS) Congress being held April 20-24, 2026, in Brisbane, Australia. Data to be presented will highlight SAB BIO’s lead program, SAB-142, a potentially best-in-class, disease-modifying, redosable immunotherapy in clinical development for newly diagnosed Stage 3 T1D patients.</p> <p>Alexandra Kropotova, M.D., http://www.streetinsider.com/Press+Releases/SAB+BIO+to+Present+Additional+Data+Supporting+the+Unique+Profile+of+SAB-142+at+the+2026+Immunology+of+Diabetes+Society+Congress/26315278.html Wed, 15 Apr 2026 08:00:00 -0400 A.09642568 O.20371933 O.49911890 SABS SABSW http://www.streetinsider.com/Press+Releases/SAB+BIO+to+Present+Additional+Data+Supporting+the+Unique+Profile+of+SAB-142+at+the+2026+Immunology+of+Diabetes+Society+Congress/26315278.html <p>MIAMI, April 15, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gbS_jsZOFMqa0pkvyM2-DxkiVRhNWSd48G20tCVO2qMdU5dmLnxdOSwLYfobbegAC0OERcXfimYYXYZbo9K2oSvyUExctEyAZHbcNVLs2NARddp5NvRLmlPI6va76INZuOjJhg8g_Rkx-J8lIQkga-AoOrBkItkMv0sw7_FWZBJlz525RUP_axAWl83G8Qp-Mt7H1F16Aje7kClIcvpwW3by4xNhBFlUYQKIPTbdyPbFpGBeoObdMR5mCPXB1iI_" rel="nofollow" target="_blank">SABS</a>), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company will give an oral presentation and multiple poster presentations at the 21st Immunology of Diabetes Society (IDS) Congress being held April 20-24, 2026, in Brisbane, Australia. Data to be presented will highlight SAB BIO’s lead program, SAB-142, a potentially best-in-class, disease-modifying, redosable immunotherapy in clinical development for newly diagnosed Stage 3 T1D patients.</p> <p>Alexandra Kropotova, M.D., http://www.streetinsider.com/Press+Releases/SAB+BIO+to+Present+Additional+Data+Supporting+the+Unique+Profile+of+SAB-142+at+the+2026+Immunology+of+Diabetes+Society+Congress/26315278.html Wed, 15 Apr 2026 08:00:00 -0400 A.09642568 O.20371933 O.49911890 SABS SABSW http://www.streetinsider.com/Press+Releases/SAB+BIO+to+Present+Additional+Data+Supporting+the+Unique+Profile+of+SAB-142+at+the+2026+Immunology+of+Diabetes+Society+Congress/26315278.html <p>MIAMI, April 15, 2026 (GLOBE NEWSWIRE) -- SAB Biotherapeutics, Inc. (Nasdaq: <a target="_blank" href="https://www.globenewswire.com/Tracker?data=gbS_jsZOFMqa0pkvyM2-DxkiVRhNWSd48G20tCVO2qMdU5dmLnxdOSwLYfobbegAC0OERcXfimYYXYZbo9K2oSvyUExctEyAZHbcNVLs2NARddp5NvRLmlPI6va76INZuOjJhg8g_Rkx-J8lIQkga-AoOrBkItkMv0sw7_FWZBJlz525RUP_axAWl83G8Qp-Mt7H1F16Aje7kClIcvpwW3by4xNhBFlUYQKIPTbdyPbFpGBeoObdMR5mCPXB1iI_" rel="nofollow" target="_blank">SABS</a>), a clinical-stage biopharmaceutical company developing a fully human anti-thymocyte immunoglobulin (hATG) for type 1 diabetes (T1D) and other autoimmune diseases, today announced that the Company will give an oral presentation and multiple poster presentations at the 21st Immunology of Diabetes Society (IDS) Congress being held April 20-24, 2026, in Brisbane, Australia. Data to be presented will highlight SAB BIO’s lead program, SAB-142, a potentially best-in-class, disease-modifying, redosable immunotherapy in clinical development for newly diagnosed Stage 3 T1D patients.</p> <p>Alexandra Kropotova, M.D., http://www.streetinsider.com/Press+Releases/SAB+BIO+to+Present+Additional+Data+Supporting+the+Unique+Profile+of+SAB-142+at+the+2026+Immunology+of+Diabetes+Society+Congress/26315278.html Wed, 15 Apr 2026 08:00:00 -0400 A.09642568 O.20371933 O.49911890 SABS SABSW